Source:http://linkedlifedata.com/resource/pubmed/id/21473061
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4
|
pubmed:dateCreated |
2011-4-7
|
pubmed:abstractText |
The search for new drugs against HCV contains new ways to obtain pro-drugs which inhibit translation and block viral proteins, and inhibit host proteins important in HCV-induced pathogenesis. This group of agents are serine protease NS3 inhibitors (telaprevir, boceprevir, R-7227, TMC-435, SCH 900518, GS-9256). The most advanced studies are developed with telaprevir and boceprevir; at present their effect in combined therapy with PegIFN-alpha and RBV in the III clinical phase is tested. The sustained viral response (SVR) was achieved at the level of 60-75%. This group of agents contains also inhibitors of NS5A domain, e.g. PPI-461 which shows antiviral and cytotoxic activity. The following prodrugs are NS3 helicase inhibitors, e.g. p14 peptide, whose IC50 equals 725 nM. Studies are continued on viral entry inhibitors (ITX-5061), therapeutic vaccines (IC-41, civaci, TG-4040, CT-1011, GI-5005) and immunomodulating preparations (ANA-773, IMO-3649, NOV-205). The agents acting on host proteins are a.o. cyclophilin inhibitors. The most advanced studies concern DEBIO 025 preparation which after phase I and II, underwent phase III of clinical studies in February 2010. Since 5 years there is a possibility to investigate the effects of these comounds in vitro with the use of Huh-7 line infected with HCV. These investigations allow to estimate the antiviral effectiveness and cytotoxicity of agents, and resistance of viral strains.
|
pubmed:language |
pol
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antiviral Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Drugs, Investigational,
http://linkedlifedata.com/resource/pubmed/chemical/NS2B protein, flavivirus,
http://linkedlifedata.com/resource/pubmed/chemical/NS3 protease, dengue virus,
http://linkedlifedata.com/resource/pubmed/chemical/Prodrugs,
http://linkedlifedata.com/resource/pubmed/chemical/Serine Endopeptidases,
http://linkedlifedata.com/resource/pubmed/chemical/Viral Nonstructural Proteins
|
pubmed:status |
MEDLINE
|
pubmed:issn |
0033-2100
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
64
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
479-84
|
pubmed:meshHeading |
pubmed-meshheading:21473061-Animals,
pubmed-meshheading:21473061-Antiviral Agents,
pubmed-meshheading:21473061-Clinical Trials as Topic,
pubmed-meshheading:21473061-Drugs, Investigational,
pubmed-meshheading:21473061-Hepacivirus,
pubmed-meshheading:21473061-Hepatitis C, Chronic,
pubmed-meshheading:21473061-Humans,
pubmed-meshheading:21473061-Prodrugs,
pubmed-meshheading:21473061-Serine Endopeptidases,
pubmed-meshheading:21473061-Viral Nonstructural Proteins,
pubmed-meshheading:21473061-Virus Replication
|
pubmed:year |
2010
|
pubmed:articleTitle |
[Inhibitors of hepatitis C virus--therapeutic possibilities].
|
pubmed:affiliation |
Pracownia Immunopatologii Zakaze? Wirusami Hepatotropowymi Zak?adu Wirusologii, Narodoweg Instytutu Zdrowia Publicznego-Pa?stwowego Zak?adu Higieny, Warszawa.
|
pubmed:publicationType |
Journal Article,
English Abstract
|